Denali Therapeutics Inc (DNLI)
16.82
-0.52
(-2.97%)
USD |
NASDAQ |
Apr 17, 16:00
16.80
-0.02
(-0.15%)
Pre-Market: 09:20
Denali Therapeutics Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
Date | Value |
---|---|
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
--
Maximum
Jun 2019
--
Average
--
Median
Jun 2019
Debt to Equity Ratio Benchmarks
Halozyme Therapeutics Inc | 17.89 |
AIM ImmunoTech Inc | 0.00 |
Perspective Therapeutics Inc | 0.0229 |
Protalix BioTherapeutics Inc | 0.6033 |
Armata Pharmaceuticals Inc | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 1.154B |
Total Liabilities (Quarterly) | 122.96M |
Shareholders Equity (Quarterly) | 1.031B |